Neutrophilic dermatosis complicating lenalidomide therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19577327.
- Also identified by DOI 10.1016/j.jaad.2008.12.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We present a case of neutrophilic dermatosis involving predominantly the lower extremities in a patient receiving lenalidomide therapy for multiple myeloma.
Medical subject headings
- Antineoplastic Agents
- Multiple Myeloma
- Sweet Syndrome
- Thalidomide